Our data, combined with the fact that irinotecan is a well-characterized anti-neoplastic drug, strongly advocate for clinical evaluations of irinotecan for the treatment of MLL-rearranged infant ALL. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.